IMPORTANT: You must read the following disclaimer before continuing. The following disclaimer applies to the attached document and you are therefore required to read this disclaimer carefully before reading, accessing or making any other use of the attached document. In accessing the attached document, you agree to be bound by the following terms and conditions, including any modifications to them from time to time, each time you receive any information from us as a result of such access. You acknowledge that this electronic transmission and the delivery of the attached document is confidential and intended for you only and you agree you will not, nor are you authorised to, forward, refer to, reproduce or publish this electronic transmission or the attached document in whole or in part in any manner whatsoever or disclose any of its contents to any other person. Failure to comply with this directive may result in a violation of the US Securities Act of 1933, as amended (the ‘‘US Securities Act’’) or the applicable laws of other jurisdictions. If you are not the intended recipient of this document, you are hereby notified that any dissemination, distribution or copying of this document is strictly prohibited. The attached document has been made available to you in electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of transmission and consequently neither PureTech Health plc (‘‘Company’’), Jefferies International Limited (‘‘Jefferies’’), Peel Hunt LLP (‘‘Peel Hunt’’), nor any of their respective members, directors, officers or employees, agents and advisers accepts any liability or responsibility whatsoever in respect of any difference between the document distributed to you in electronic format and the hard copy version. You are reminded that you have accessed the attached document on the basis that you are a person into whose possession this document may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located and you may not nor are you authorised to deliver this document, electronically or otherwise, to any other person. This document has been prepared by, and is the sole responsibility of, the directors of the Company in connection with the proposed offer (‘‘Offer’’) of ordinary shares in the Company (‘‘Ordinary Shares’’) and the proposed admission of the Ordinary Shares to the premium listing segment of the Official List maintained by the Financial Conduct Authority and to trading on the main market of the London Stock Exchange plc. The attached document is only addressed to and directed at persons in member states of the European Economic Area who are ‘‘qualified investors’’ within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) (‘‘Qualified Investors’’). In the United Kingdom, this document is being distributed only to, and is directed only at, Qualified Investors (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ‘‘Order’’) and Qualified Investors who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and (ii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as ‘‘Relevant Persons’’). The attached document must not be acted on or relied on (i) in the United Kingdom, by persons who are not relevant persons; and (ii) in any member state of the European Economic Area other than the United Kingdom, by persons who are not Qualified Investors. Any investment or investment activity to which this document relates is available only to (i) in the United Kingdom, Relevant Persons; and (ii) in any member state of the European Economic Area other than the United Kingdom, Qualified Investors. Nothing in this electronic transmission or the attached document constitutes an offer of securities for sale in any jurisdiction where it is unlawful to do so, and in particular, is not for distribution in Australia, Canada (except in compliance with an exemption from applicable securities laws), Japan, South Africa or the United States of America or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. Confirmation of Your Representation: The attached document is delivered to you on the basis that you are deemed to have represented to the Company, Jefferies and Peel Hunt that (i) you are outside the United States, (ii) if you are in the UK, you are a Relevant Person, and/or a Relevant Person who is acting on behalf of, Relevant Persons in the United Kingdom and/or Qualified Investors to the extent you are acting on behalf of persons or entities in the UK or the EEA; (iii) if you are in any member state of the European Economic Area other than the UK, you are a Qualified Investor and/ or a Qualified Investor acting on behalf of, Qualified Investors or Relevant Persons, to the extent you are acting on behalf of persons or entities in the EEA or the UK; (iv) you are acting on behalf of, or you are an institutional investor that is eligible to receive this document and (v) that you consent to delivery by electronic transmission. In order to be eligible to view the attached document you must be outside the United States. Restrictions: Nothing in this electronic transmission constitutes an offer of securities for sale to persons other than specified qualified institutional buyers to whom it is directed and access has been limited so that it shall not constitute a general solicitation. If you have gained access to this transmission contrary to the foregoing restrictions, you will be unable to purchase any of the securities described therein. NOTHING IN THIS ELECTRONIC TRANSMISSION OR THE ATTACHED DOCUMENT CONSTITUTES AN OFFER FOR SALE OF SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY OTHER STATE OR OTHER JURISDICTION OF THE UNITED STATES OR IN ANY OTHER JURISDICTION AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN OR INTO THE UNITED STATES. THE ORDINARY SHARES ARE BEING OFFERED AND SOLD OUTSIDE THE UNITED STATES IN OFFSHORE TRANSACTIONS, AS DEFINED IN, AND IN COMPLIANCE WITH, REGULATION S UNDER THE SECURITIES ACT. YOU MAY NOT, NOR ARE YOU AUTHORISED TO, COPY OR REPRODUCE THE ATTACHED DOCUMENT IN WHOLE OR IN PART IN ANY MANNER WHATSOEVER OR DELIVER, DISTRIBUTE OR FORWARD THE DOCUMENT OR DISCLOSE ANY OF ITS CONTENTS TO ANY OTHER PERSON. IF YOU ARE NOT THE INTENDED RECIPIENT OF THIS DOCUMENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS DOCUMENT IS STRICTLY PROHIBITED. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. Neither Jefferies, Peel Hunt nor any of their respective affiliates accepts any responsibility whatsoever for the contents of this electronic transmission or the attached document or for any other statement made or purported to be made by it, or on its behalf, in connection with the Company or the Offer referred to therein. Each of Jefferies and Peel Hunt and their respective affiliates accordingly disclaims all and any liability whether arising in tort, contract or otherwise which they might otherwise have in respect of such electronic transmission, attached document or any such statement. No representation or warranty, express or implied, is made by either Jefferies or Peel Hunt or any of their respective affiliates as to the accuracy, completeness or sufficiency of the information set out in this electronic transmission or the attached document. Jefferies and Peel Hunt, each of which are authorised and regulated in the United Kingdom by the FCA, are acting exclusively for the Company and no-one else in relation to the Offering and Admission (whether or not such person is a recipient of this document) and will not regard anyone other than the Company as their respective client and will not be responsible to anyone other than the Company for providing the protections afforded to the respective clients of Jefferies and Peel Hunt nor for providing advice or otherwise in relation to any matter contained in this document or any matter, transaction or arrangement referred to in it. PURETECH – Giving Life to Science PROSPECTUS — 19 JUNE 2015 Giving Life to Science PROSPECTUS • 19 PROSPECTUS • 19 JUNE 2015 PureTech • 501 Boylston Street, Suite 6102 • Boston, MA 02116 PureTech Prospectus Cover FINAL.indd 2 6/3/15 12:11 PM This document comprises a prospectus (the ‘‘Prospectus’’) relating to PureTech Health plc (the ‘‘Company’’ or ‘‘PureTech’’) prepared in accordance with the prospectus rules (the ‘‘Prospectus Rules’’) of the Financial Conduct Authority (‘‘FCA’’) made under section 73A of the Financial Services and Markets Act 2000 (as amended) (‘‘FSMA’’). This document has been approved by the FCA in accordance with section 87A of FSMA and made available to the public as required by Rule 3.2 of the Prospectus Rules. The Company and the Directors, whose names appear at paragraph 1 (Directors) of Part IX (Directors, Senior Managers and Corporate Governance) of this document, accept responsibility for the information contained in this document. To the best of the knowledge and belief of the Company and the Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of such information.